WALD EN UNIVER SIT Y — COLLEGE OF NUR SING
NURS6521 / NURS 6521
Final Exam Q & A:
Advanced
Pharmacology
A comprehensive 100-question final examination covering
pharmacokinetics, pharmacodynamics, pharmacogenomics,
autonomic and CNS pharmacology, cardiovascular and renal
pharmacology, endocrine and metabolic agents, antimicrobials,
respiratory and GI medications, pain management, special
populations, and adverse effects with clinical reasoning aligned
with the 2026–2027 MSN-NP curriculum.
Total Questions: 100 | Format: Multiple Choice (A–D)
Academic Year: 2026–2027 | Cognitive Levels: Recall / Application / Analysis
C O N F I D E N T I A L E X A M I N AT I O N M AT E R I A L LATES T 20 27 ED ITION
, NURS6521 / NURS 6521: Final Exam Q & A — Advanced
Pharmacology
Walden University | 100 Questions | Multiple Choice (A–D)
Latest 2026/2027 Edition
Instructions: Select the best answer for each question. Each question has four options (A–D). Only one answer is
correct. The correct answer and rationale are provided after each question for study purposes.
NURS6521 Advanced Pharmacology — Final Exam Q&A Page 1
, Section 1: Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
(Q1–Q15)
Q1. A nurse practitioner is prescribing a medication that undergoes extensive first-pass metabolism. Which
route of administration would bypass this effect and achieve 100% bioavailability?
A. Oral (PO)
B. Intramuscular (IM)
C. Intravenous (IV) **[CORRECT]**
D. Sublingual (SL)
Correct Answer: C
Rationale: Intravenous administration bypasses both the gastrointestinal tract and hepatic first-pass metabolism, resulting
in 100% bioavailability. Oral medications undergo first-pass hepatic metabolism, significantly reducing bioavailability.
Sublingual (SL) does bypass first-pass metabolism but bioavailability depends on the drug; IV provides guaranteed 100%.
Q2. A patient with chronic kidney disease (GFR 25 mL/min) is prescribed gabapentin. Which
pharmacokinetic alteration requires dose adjustment?
A. Decreased absorption in the GI tract
B. Reduced hepatic metabolism of the drug
C. Decreased renal excretion leading to drug accumulation **[CORRECT]**
D. Increased protein binding increasing free drug levels
Correct Answer: C
Rationale: Gabapentin is primarily excreted unchanged by the kidneys through glomerular filtration. In patients with
impaired renal function, the drug accumulates, increasing the risk of CNS toxicity (dizziness, sedation, ataxia). The dose
must be adjusted based on creatinine clearance. Hepatic metabolism and protein binding are not the primary concerns for
gabapentin.
Q3. A nurse practitioner is reviewing a patient's medication regimen and notes they are a CYP2D6 poor
metabolizer. Which medication interaction is most concerning?
A. Decreased effectiveness of codeine due to inability to convert it to morphine **[CORRECT]**
B. Increased risk of serotonin syndrome when combining fluoxetine and tramadol
C. Decreased warfarin metabolism leading to elevated INR
D. Increased metabolism of clopidogrel reducing its antiplatelet effect
Correct Answer: A
Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine for analgesic effect. CYP2D6
poor metabolizers cannot effectively convert codeine to its active form, resulting in therapeutic failure. This is a critical
pharmacogenomic consideration. Tramadol similarly requires CYP2D6 activation. Warfarin is primarily metabolized by
CYP2C9, and clopidogrel activation involves CYP2C19.
Q4. A patient taking phenytoin (Dilantin) has a serum level of 22 mcg/mL (therapeutic range: 10–20
mcg/mL). The nurse practitioner should assess for which signs of toxicity?
A. Tremor, nystagmus, ataxia, and confusion **[CORRECT]**
B. Bradycardia, hypotension, and bronchoconstriction
C. Nausea, vomiting, and abdominal pain only
D. Hyperreflexia and muscle rigidity
Correct Answer: A
Rationale: Phenytoin has a narrow therapeutic index (10–20 mcg/mL). Toxicity presents with nystagmus (earliest sign),
ataxia, diplopia, confusion, and in severe cases, tremor and seizures. This follows a zero-order kinetics pattern at
NURS6521 Advanced Pharmacology — Final Exam Q&A Page 2
NURS6521 / NURS 6521
Final Exam Q & A:
Advanced
Pharmacology
A comprehensive 100-question final examination covering
pharmacokinetics, pharmacodynamics, pharmacogenomics,
autonomic and CNS pharmacology, cardiovascular and renal
pharmacology, endocrine and metabolic agents, antimicrobials,
respiratory and GI medications, pain management, special
populations, and adverse effects with clinical reasoning aligned
with the 2026–2027 MSN-NP curriculum.
Total Questions: 100 | Format: Multiple Choice (A–D)
Academic Year: 2026–2027 | Cognitive Levels: Recall / Application / Analysis
C O N F I D E N T I A L E X A M I N AT I O N M AT E R I A L LATES T 20 27 ED ITION
, NURS6521 / NURS 6521: Final Exam Q & A — Advanced
Pharmacology
Walden University | 100 Questions | Multiple Choice (A–D)
Latest 2026/2027 Edition
Instructions: Select the best answer for each question. Each question has four options (A–D). Only one answer is
correct. The correct answer and rationale are provided after each question for study purposes.
NURS6521 Advanced Pharmacology — Final Exam Q&A Page 1
, Section 1: Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
(Q1–Q15)
Q1. A nurse practitioner is prescribing a medication that undergoes extensive first-pass metabolism. Which
route of administration would bypass this effect and achieve 100% bioavailability?
A. Oral (PO)
B. Intramuscular (IM)
C. Intravenous (IV) **[CORRECT]**
D. Sublingual (SL)
Correct Answer: C
Rationale: Intravenous administration bypasses both the gastrointestinal tract and hepatic first-pass metabolism, resulting
in 100% bioavailability. Oral medications undergo first-pass hepatic metabolism, significantly reducing bioavailability.
Sublingual (SL) does bypass first-pass metabolism but bioavailability depends on the drug; IV provides guaranteed 100%.
Q2. A patient with chronic kidney disease (GFR 25 mL/min) is prescribed gabapentin. Which
pharmacokinetic alteration requires dose adjustment?
A. Decreased absorption in the GI tract
B. Reduced hepatic metabolism of the drug
C. Decreased renal excretion leading to drug accumulation **[CORRECT]**
D. Increased protein binding increasing free drug levels
Correct Answer: C
Rationale: Gabapentin is primarily excreted unchanged by the kidneys through glomerular filtration. In patients with
impaired renal function, the drug accumulates, increasing the risk of CNS toxicity (dizziness, sedation, ataxia). The dose
must be adjusted based on creatinine clearance. Hepatic metabolism and protein binding are not the primary concerns for
gabapentin.
Q3. A nurse practitioner is reviewing a patient's medication regimen and notes they are a CYP2D6 poor
metabolizer. Which medication interaction is most concerning?
A. Decreased effectiveness of codeine due to inability to convert it to morphine **[CORRECT]**
B. Increased risk of serotonin syndrome when combining fluoxetine and tramadol
C. Decreased warfarin metabolism leading to elevated INR
D. Increased metabolism of clopidogrel reducing its antiplatelet effect
Correct Answer: A
Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine for analgesic effect. CYP2D6
poor metabolizers cannot effectively convert codeine to its active form, resulting in therapeutic failure. This is a critical
pharmacogenomic consideration. Tramadol similarly requires CYP2D6 activation. Warfarin is primarily metabolized by
CYP2C9, and clopidogrel activation involves CYP2C19.
Q4. A patient taking phenytoin (Dilantin) has a serum level of 22 mcg/mL (therapeutic range: 10–20
mcg/mL). The nurse practitioner should assess for which signs of toxicity?
A. Tremor, nystagmus, ataxia, and confusion **[CORRECT]**
B. Bradycardia, hypotension, and bronchoconstriction
C. Nausea, vomiting, and abdominal pain only
D. Hyperreflexia and muscle rigidity
Correct Answer: A
Rationale: Phenytoin has a narrow therapeutic index (10–20 mcg/mL). Toxicity presents with nystagmus (earliest sign),
ataxia, diplopia, confusion, and in severe cases, tremor and seizures. This follows a zero-order kinetics pattern at
NURS6521 Advanced Pharmacology — Final Exam Q&A Page 2
